| 摘要 |
The present invention provides a pharmaceutical composition for administering simultaneously, separately or sequentially N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropa namide or a pharmacologically acceptable salt thereof, and a HMG-CoA reductase inhibitor. |
